ASCVD risk stratification modifies the effect of HbA1c on cardiovascular events among patients with type 2 diabetes mellitus with basic to moderate risk.

Hongmei ZhangLi QinChang-Sheng ShengYixin NiuHongxia GuShuai LuZhen YangJingyan TianQing Su

Published in: BMJ open diabetes research & care (2020)

HbA1c of 7.0%-8.0% may result in a significantly higher CVD risk among patients with T2DM with moderate baseline ASCVD risk, which support the use of HbA1c combined with baseline ASCVD risk assessment to determine future glucose-lowering treatment decisions among patients with T2DM with basic to moderate risk.

Keyphrases

cardiovascular events
risk assessment
coronary artery disease
cardiovascular disease
type diabetes
metabolic syndrome
heavy metals
human health